Clinical trial platform’s AI and navigator-led model bridges gap in pre-approval treatment access across 128 countries.

On International Clinical Trials Day, myTomorrows has announced it has now successfully matched over 15,000 patients to clinical trials or Expanded Access Programs (EAPs). This was across 128 countries which the company says is a milestone that reflects both the scale and precision of its AI-driven patient-matching platform.

The Amsterdam-based company combines algorithmic trial-matching technology with multilingual, medically trained patient navigators who help individuals navigate a complex landscape of investigational treatments.

To date, the platform has supported 15,375 patient matches and worked with nearly 2,500 physicians worldwide to improve access to pre-approval treatment options – often for patients facing limited or no approved alternatives.

With more than half a million clinical trials recruiting globally and thousands of experimental therapies in the pipeline, connecting patients to relevant options remains a persistent challenge. myTomorrows’ platform addresses this by using AI to match patient profiles to trial eligibility with up to 98% accuracy. The system pulls data from key trial registries such as ClinicalTrials.gov, EudraCT, and ISRCTN, and integrates with electronic health records to deliver near-instant, compliant matches.

“In 2024 alone, our team conducted more than 5,000 personalised calls with patients and families,” said Michel van Harten, CEO of myTomorrows. “This milestone isn’t about platform sign-ups — it’s about real people who’ve been matched, referred, and enrolled in clinical studies or access programmes. It’s a tangible step forward in patient-centric drug development.”

The company’s reach continues to expand, recently launching services in the Asia-Pacific region and forming a strategic partnership with Scout Clinical to facilitate cross-border trial participation. It also works directly with patient advocacy groups such as The ALS Association, CureLGMD2i, and Pancreatic Cancer Europe to help build awareness and accessibility for underrepresented communities.